Summary
Between 1960 and 1976 117 patients underwent pituitary implantation with yttrium-90 (90Y) for treatment of proliferative retinopathy at the Hammersmith Hospital, London. Mean age at operation was 35±11 years (mean±SD), and mean duration of diabetes 18.6±10.0 years. Mean insulin dosage prior to implant was 67.2±24 units, falling to 30.4±14.9 units post-implant. Thirty-two per cent of patients are still living, 60% are deceased and 8% are lost to follow-up. The 5-year survival rate was 82%. Of the causes of death, 21% died of infection, adrenal insufficiency or hypoglycaemia, 12% of renal failure, and 47% of myocardial or cerebral vascular disease. Ophthalmological follow-up was carried out on the 100 patients operated on between 1965 and 1976. The mean age of this group at implant was 35±10.5 years, and mean duration of diabetes 17.2±8.7 years. Visual acuity in the better eye at operation was 6/12 or better in 84% of patients, and this percentage remained similar at the time of the 5 and 10 year follow-up. Blindness (6/60 or worse) in both eyes was present in 12% of patients at the time of 5 and 10 year assessments. By 5 years new vessels on the disc had improved from a mean grading of 2.7±1.6 to 0.8±1.2 (p<0.001), and by 10 years there was no disc neovascularisation in any eye. There was a similar improvement in the grading of hard exudates, microaneurysms and haemorrhages, but there was an increase in fibrous retinitis proliferans. It is concluded that pituitary ablation was an effective method of treating proliferative retinopathy, and may have had a beneficial effect on other microvascular complications.
Article PDF
Similar content being viewed by others
References
Poulsen JD (1953) Diabetes and anterior pituitary deficiency. Diabetes 2: 7–12
Luft R, Olivecrona H (1955) Hypophysectomy in man: further experience in severe diabetes mellitus. Br Med J 2: 752–56
Fraser TR, Joplin GF, Lewis JW, Morrison R, Steiner RE (1959) Needle implantation of yttrium seeds for pituitary ablation in cases of secondary cancer. Lancet 1: 382
Joplin GF, Hill DW, Scott DJ, Fraser TR (1962) Pituitary ablation in the treatment of diabetic retinopathy. In: Pyke DA (ed) Disorders of Carbohydrate Metabolism. Pitman, London Massachusetts, pp 207–212
Joplin GF, Fraser TR, Hill DW, Oakley NW, Scott DJ, Doyle FH (1965) Pituitary ablation for diabetic retinopathy. Q J Med 34: 443–65
Joplin GF, Oakley NW, Hill DW, Kohner EM, Fraser TR (1967) Diabetic retinopathy: comparison of disease remission induced by various degrees of pituitary ablation by Y-90. Diabetologia 3: 406–12
Oakley NW, Hill DW, Joplin GF, Kohner EM, Fraser TR (1969) The treatment of diabetic retinopathy by pituitary implantation of radioactive yttrium. In: Goldberg MF, Fine SL (eds) Symposium on the treatment of diabetic retinopathy, Airlie House, Warrington, Virginia, Sept 29–Oct 1, 1968. US Government Printing Office, Washington DC, pp 317–29
Kohner EM, Dollery CT, Fraser TR, Bulpitt CJ (1970) Effect of pituitary ablation on diabetic retinopathy studied by fluorescence angiography. Diabetes 19: 703–14
Panisset A, Kohner EM, Cheng H, Fraser TR (1971) New vessels arising from the optic disc: response to pituitary implantation by yttrium-90 implant. Diabetes 20: 824–33
Kohner EM, Joplin GF, Blach RK, Cheng H, Fraser TR (1972) Pituitary ablation in the treatment of diabetic retinopathy: a randomised trial. Trans Ophthalmol Soc UK 92: 72–90
Kohner EM, Hamilton AM, Joplin GF, Fraser TR (1976) Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes 25: 1054–10
Harsoulis P, Marshall JC, Kuku SF, Burke CW, London DR, Fraser TR (1973) Combined test for assessment of anterior pituitary function. Br Med J 4: 326–39
Oakley NW, Hill DW, Joplin GF, Kohner EM, Fraser TR (1967) Diabetic retinopathy I: the assessment of severity and progress by comparison with a set of standard fundus photographs. Diabetologia 3: 402–5
Kohner EM, Panisset A, Cheng H, Fraser TR (1971) Diabetic retinopathy: new vessels arising from the optic disc: grading system and natural history. Diabetes 20: 816–23
Shalet SM, Beardwell CG, MacFarlane IA, Morris Jones PH (1977) Endocrine morbidity in adults treated with cerebral irradiation for brain tumours during childhood. Acta Endocrinol 84: 673–80
Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Hansen AP, Orskov H, Osterby R (1970) Diabetes, diabetic angiopathy and growth hormone. Lancet 2: 131–33
Levin ME, Boisseau VC, Avioli LV (1976) Effects of diabetes mellitus on bone mass in juvenile and adult onset diabetes. N Engl J Med 294: 241–45
Barnes AJ, Kohner EM, Bloom SR, Johnston DG, Alberti KGMM, Smythe P (1978) Importance of pituitary hormones in the aetiology of diabetic ketoacidosis. Lancet 1: 1171–74
Caird FI (1969) Mortality in patients with diabetic retinopathy. In: Caird FI, Pirie A, Ramsell TG (eds) Diabetes and the eye. Blackwell, Oxford, pp 98–112
Davis MD, Hiller R, Magli YM (1979) Prognosis for life in patients with retinopathy: relation to severity of retinopathy. Trans Am Ophthalmol Soc 77: 144–70
Rogot E, Goldberg ID, Goldstein H (1966) Survivorship and causes of death among the blind. J Chronic Dis 19: 179–97
Knatterud GL (1983) Mortality experience in the diabetic retinopathy study. Isr J Med Sci 19: 424–28
Deckert T, Simonsen E, Poulsen JE (1967) Prognosis for vision in proliferative retinopathy in juvenile diabetes. Diabetes 16: 728–33
Entmacher PS, Root HF, Marks HH (1964) Longevity of diabetic patients in recent years. Diabetes 13: 373–77
Keen H, Rose G, Pyke DA, Boyns D, Chlouverakis C, Mistry S (1965) Blood sugar and arterial disease. Lancet 2: 505–58
Ireland JT, Partnaik BK, Duncan JJP (1967) Effect of pituitary ablation on renal arteriolar and glomerular lesions in diabetes. Diabetes 25: 636–42
Greenwood RH, Ireland JT, Jones DJ, Mahler RF (1975) Diabetic complications in a patient with coexisting hypopituitarism. Diabetes 24: 1027–31
Root HF, Mirsky S, Ditzel J (1959) Proliferative retinopathy in diabetes mellitus: a review of eight hundred and forty-seven cases. J Am Med Soc 169: 903–9
Deckert T, Poulsen JE, Larsen M (1978) Prognosis of diabetics with diabetes onset before the age of 31. Diabetologia 14: 363–70
Lundbaek K, Malmros R, Andersen HC (1969) Hypophysectomy for diabetic retinopathy: a controlled clinical trial. In: Symposium on the treatment of diabetic retinopathy, Airlie House, Warrington, Virginia, Sept29–Oct 1, 1968. Goldberg MF, Fine SL (eds) US Government Printing Office, Washington DC, pp 291–311
Teuscher A, Eschen F, Konig H, Zahnd T (1970) Long term effects trans-sphenoidal hypophysectomy on growth hormone, renal function and eyeground in patients with diabetic retinopathy. Diabetes 19: 502
Bradley RF, Rees SB, Fager SG (1965) Pituitary ablation in the treatment of diabetic retinopathy. Med Clin North Am 49: 1105–24
Beetham WP (1963) Visual prognosis of proliferating retinopathy. Br J Ophthalmol 47: 611–19
Valone JA, McMeel JW (1978) Severe adolescent onset proliferative diabetic retinopathy: the effect of pituitary ablation. Arch Ophthalmol 96: 1349–53
Caird FI, Garret CJ (1963) Prognosis for vision in diabetic retinopathy. Diabetes 12: 389–97
Field RA, McMeel JW, Sweet WH, Schepens CL (1969) Hypophyseal stalk section for angiopathic diabetic retinopathy. In: Goldberg MF, Fine SL (eds) Symposium on the treatment of diabetic retinopathy, Airlie House, Warrington, Virginia, Sept 29–Oct 1. US Government Printing Office, Washington DC, pp 213–25
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sharp, P.S., Fallon, T.J., Brazier, O.J. et al. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 30, 199–207 (1987). https://doi.org/10.1007/BF00270416
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00270416